The Fight Against Cancer: Neoantigens, Tumor Escape and the Tumor Microenvironment

A conversation with JOHN WEST, CEO of Personalis, Inc. in Menlo, Park, California

Nature, October 26, 2017

Tumours may be initiated by mutations in their driver genes, but their clinical outcomes are strongly influenced by the battle between neoantigens and the immune system’s response to them. Checkpoint inhibitors and personal cancer vaccines are rapidly growing areas of pharmaceutical research.

Personalis, Inc. is a provider of advanced genomics solutions for immuno-oncology. The company has developed the ACE ImmunoID Platform, which combines whole exome and transcriptome sequencing with analytics, to help inform clinical and translational research through robust, comprehensive molecular data.